Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
266
Participants
Timeline
Start Date
August 11, 2025
Primary Completion Date
July 30, 2027
Study Completion Date
July 30, 2027
Conditions
Advanced Solid Tumors
Interventions
DRUG
SYS6045
SYS6045, IV Q3W
Trial Locations (1)
024
The First Hospital of China Medical University, Shenyang